More treatments from Teva

Israel’s Teva has launched in the US the generic equivalent to Gleevec (imatinib mesylate) for the treatment of leukemia and other cancer-related diseases. Also, Europe has approved Teva’s CINQAERO (reslizumab) – the first intravenous anti-IL-5 biologic therapy for severe eosinophilic asthma.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *